GI Stimulants

Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives

Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives

Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia...

These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying

These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying

These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refrac...

These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying

Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes

Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes